Kyntra Bio (NASDAQ:KYNB) Downgraded by Zacks Research to Strong Sell

Kyntra Bio (NASDAQ:KYNB) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday, Zacks reports.

Other equities analysts have also issued reports about the stock. Maxim Group began coverage on shares of Kyntra Bio in a research report on Tuesday. They set a “buy” rating and a $35.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $43.00 price target on shares of Kyntra Bio in a report on Tuesday, September 1st. Oppenheimer assumed coverage on Kyntra Bio in a research note on Monday, July 6th. They issued an “outperform” rating and a $35.00 price objective on the stock. Lake Street Capital began coverage on Kyntra Bio in a research note on Thursday, September 17th. They issued a “buy” rating and a $41.00 price objective on the stock. Finally, Weiss Ratings downgraded Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. Five analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $36.80.

Kyntra Bio Price Performance

Kyntra Bio stock opened at $5.87 on Monday. The stock has a market cap of $23.77 million, a price-to-earnings ratio of 0.13 and a beta of 1.05. Kyntra Bio has a 1 year low of $5.62 and a 1 year high of $11.65. The firm has a 50-day moving average of $7.26 and a two-hundred day moving average of $7.12.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kyntra Bio stock. ADAR1 Capital Management LLC bought a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned 0.26% of Kyntra Bio as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 72.71% of the company’s stock.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.